prikaz prve stranice dokumenta High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma
  Download
PDF 485.63 KB
Scientific paper - Original scientific paper
High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma
Annals of Hematology, 95 (2016), 7; 1129-1136. https://doi.org/10.1007/s00277-016-2676-0
Aurer, Igor; Nemet, Damir; Mitrović, Zdravko; Dujmović, Dino; Bašić-Kinda, Sandra; Radman, Ivo; Sertić, Dubravka; Šantek, Fedor; Kralik, Marko; Dotlić, Snježana; Mazić, Sanja; Labar, Boris

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Aurer, I., Nemet, D., Mitrović, Z., Dujmović, D., Bašić Kinda, S., Radman, I. ... Labar, B. (2016). High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. Annals of Hematology, 95. (7), 1129-1136. doi: 10.1007/s00277-016-2676-0

Aurer, Igor, et al. "High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma." Annals of Hematology, vol. 95, no. 7, 2016, pp. 1129-1136. https://doi.org/10.1007/s00277-016-2676-0

Aurer, Igor, Damir Nemet, Zdravko Mitrović, Dino Dujmović, Sandra Bašić Kinda, Ivo Radman, Dubravka Sertić, et al. "High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma." Annals of Hematology 95, no. 7 (2016): 1129-1136. https://doi.org/10.1007/s00277-016-2676-0

Aurer, I., et al. (2016) 'High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma', Annals of Hematology, 95(7), pp. 1129-1136. doi: 10.1007/s00277-016-2676-0

Aurer I, Nemet D, Mitrović Z, Dujmović D, Bašić Kinda S, Radman I, and sur.. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. Annals of Hematology [Internet]. 2016 June [cited 2024 November 29];95(7):1129-1136. doi: 10.1007/s00277-016-2676-0

I. Aurer, et al., "High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma", Annals of Hematology, vol. 95, no. 7, pp. 1129-1136, June 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:978993. [Accessed: 29 November 2024]

Metadata
Title (english)High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma
AuthorIgor Aurer
AuthorDamir Nemet
AuthorZdravko Mitrović
AuthorDino Dujmović
AuthorSandra Bašić-Kinda
AuthorIvo Radman
AuthorDubravka Sertić
AuthorFedor Šantek
AuthorMarko Kralik
AuthorSnježana Dotlić
AuthorSanja Mazić
AuthorBoris Labar
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem cell transplantation (ASCT). Optimal chemotherapy is unknown. We retrospectively analyzed outcomes of 58 patients treated with 2 cycles of high-dose ifosfamide and mitoxantrone (HDIM). HDIM consisted of ifosfamide 5 g/m(2)/day and MESNA 5 g/m(2)/day in continuous 24-h infusion (days 1 and 2), MESNA 2.5 g/m(2) over 12 h (day 3), and mitoxantrone 20 mg/m(2) (day 1) administered every 2 weeks. Stem cells were collected after the first cycle. Responding patients proceeded to ASCT. Toxicity was acceptable. Stem cell mobilization was successful in 96 % of patients. Overall response rate was 74 % (89 % in relapsing and 45 % in refractory patients) with 31 % complete remissions. After a median follow-up of 54 months, 5-year event-free survival was 56 % (69 % for relapsing and 35 % for refractory patients), and 5-year overall survival was 67 % (73 % for relapsing and 55 % for refractory patients). Significant adverse prognostic factors were refractoriness to previous therapy and HDIM failure. No differences in outcomes were noted between patients with early and late relapses or between complete and partial responders. HDIM is a well-tolerated and effective regimen for relapsed and refractory HL with excellent stem cell mobilizing properties. Patients failing HDIM may still benefit from other salvage options.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleAnnals of Hematology
Numberingvol. 95, no. 7, pp. 1129-1136
p-ISSN0939-5555
DOIhttps://doi.org/10.1007/s00277-016-2676-0
URN:NBNurn:nbn:hr:105:978993
Publication2016-06
Document URLhttps://doi.org/10.1007/s00277-016-2676-0
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:52:21